Our Take
This is a standard biotech licensing deal: one company's epitope discovery paired with another's manufacturing platform. The science is sound, the partnership is logical, but there is no published clinical or preclinical data showing the combined approach works better than existing ADCs.
Why it matters
Antibody-drug conjugates (ADCs) are now a standard oncology pillar. The commercial bet here is that tumor-specific epitope selection reduces off-target toxicity and improves tolerability, which matters because ADC safety limits their dose and breadth of use.
Do this week
ADC development teams: audit your current epitope screening methods against Stipple's Pointillist Platform claims once first-in-human data from STP-100 is public (likely 2026–2027); do not switch platforms on partnership announcements alone.
Stipple Bio signs multi-target licensing deal with Lonza
Stipple Bio and Lonza have agreed to co-develop next-generation antibody-drug conjugates (ADCs) for oncology. Under the agreement, Stipple gains access to Lonza's GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, and toxSYN linker payloads. Lonza will manufacture components tied to its proprietary platforms; Stipple handles R&D, full ADC manufacturing, and commercialization. Lonza is eligible to receive upfront payments, clinical and regulatory milestones, and royalties on net sales.
The collaboration centers on Stipple's Pointillist Platform, which identifies tumor-specific cell surface epitopes. According to Stipple, the same DNA can produce different protein presentations on tumor versus normal cells, exposing epitopes that are tumor-selective. The company says its platform identifies these epitopes and designs antibody binders that attach exclusively to tumor cells, reducing on-target/off-tumor toxicity.
Stipple's lead program, STP-100, will advance under this agreement as a candidate first-in-class or best-in-class ADC.
The real test: does epitope selectivity improve clinical outcomes?
ADCs have become a major pillar of cancer treatment, but they carry a known tradeoff: potency versus tolerability. The linker and payload can kill tumor cells effectively, but any binding to healthy tissue expressing the same antigen causes collateral damage. This on-target/off-tumor toxicity limits dosing and restricts which patients and tumor types benefit.
Stipple's pitch is that identifying and targeting tumor-unique epitopes sidesteps this problem. If tumor cells genuinely express epitopes absent from healthy tissue, then even a potent ADC could achieve higher efficacy without added toxicity. That is a rational hypothesis. It is not yet evidence.
Lonza's manufacturing and conjugation platforms are clinically validated and widely used. The value of pairing them with a new epitope discovery method depends entirely on whether Stipple's Pointillist approach actually finds usable tumor-selective epitopes at scale and whether ADCs built around them outperform existing standard-of-care options in human trials.
No clinical or preclinical benchmarks are published alongside this announcement. STP-100's first-in-human data will be the moment to assess whether the science delivers on the promise.
What teams building ADCs should watch
For ADC developers, this partnership is noteworthy as validation that epitope discovery is a competitive lever in ADC design. Lonza is a preferred manufacturing partner for many programs, so a partnership here signals Stipple's platform is serious enough to integrate into a partner's development path.
However, partnership announcements are not clinical proof. ADC toxicity profiles are determined in Phase 1 and Phase 2 trials. Until STP-100 shows that Pointillist-selected epitopes outperform standard antigen selection in human dosing, tolerability, and response, the competitive advantage is theoretical.
Teams evaluating epitope discovery tools or considering a switch from current screening methods should wait for published preclinical or Phase 1 data before committing resources.